๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE ยท Real-Time Price ยท USD
17.62
+0.92 (5.51%)
Nov 18, 2026, 1:05 PM EST - Market open
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

2027 guidance targets GAAP profitability and positive operating cash flow, supported by established-product growth and two gene-therapy launches. Setrusumab may require additional prospective data, while launch activity and QTC expansion continue.

Maury Raycroft
Biotech Analyst, Jefferies

Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I am happy to welcome the team from Ultragenyx. We have Emil Kakkis, the CEO, and Howard Horn, the Chief Financial Officer. Thanks so much for joining us today.

Emil Kakkis
CEO, Ultragenyx

Happy to be here.

Howard Horn
CFO, Ultragenyx

Thanks, Maury.

Maury Raycroft
Biotech Analyst, Jefferies

We are going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to Ultragenyx.

Emil Kakkis
CEO, Ultragenyx

Sure. Ultragenyx is a company working on rare and ultra-rare disease treatments. We have been on the public markets for 12 years, and we have six approved programs in that time, including two gene therapies, monoclonal antibody, enzyme, and small molecule treatments for a variety of rare and ultra-rare diseases. We work in bone, endocrine, neuro, and also in inborn errors of metabolism. We are a diversified global company. We have commercial operations in North America, South America, Europe, Middle East, and Japan. We believe in exploring the full global markets as a way to build our business. Our base business of four original products have been growing at around 20% a year for the last few years, and we just added two new gene therapy approvals, which we can talk more about. They are launching now. With those approvals, we also got two PRVs.

We had a program, Angelman treatment for GTX-102, that did miss recently, which led to a need for cost containment and controls, which we have implemented, which put us on track to be next year a profitable company. We expect to be $1 billion plus in revenue, and to be meaningfully profitable, and to be able to operate a more narrowed, focused R&D footprint going forward. We are excited about this next stage of getting to profitability, which was, I think, our original plan. We continue to work on an R&D platform which will generate appropriate upside, but we are also being driven by our commercial franchise. We can talk more about the launches and the other programs as we get through.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Yeah, I think that is a great intro, a lot to talk about. Maybe starting first with commercial and profitability, you have reiterated the GAAP profitability and positive operating cash flow in 2027. Can you walk us through the major assumptions underpinning that guidance? When we talk about the base business growth contributions from GENGLYCOS and FAYUVI, and the level of pipeline investment, particularly if setrusumab requires additional development.

Emil Kakkis
CEO, Ultragenyx

Yeah, I think I would just start by saying that we always had a plan to become profitable. In this case, we need to do it at that moment in time without an Angelman revenue source. But we had enough revenue to base it, and we could right-size our development organization and get us there, and to meaningful profitability. But I will let Howard put together some of the pieces of that story, since he has been intimately helping putting that together.

Howard Horn
CFO, Ultragenyx

Maury, you are right. We have guided to full-year GAAP profitability in 2027. We also said positive cash from operations. That is a real turning point for the company. The assumptions to get there are that the current four programs continue to grow. As Emil mentioned, they have been growing well for many years. Then some supplementation from the two gene therapy launches to build the top line. Then we had recently given guidance on R&D and SG&A, where we talked about ceilings of $350 million next year for R&D and a ceiling of $375 million next year for SG&A. Those are the building blocks of it.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Yeah, that makes sense. Maybe starting with the expense guidance there, you are saying those are ceilings, so that implies the floor could be lower. I guess, what can you say about those ranges then?

Howard Horn
CFO, Ultragenyx

At this point, we have just commented on the ceiling part of it. But what we really wanted to do is give people comfort that we had turned the corner, and I hope that came through.

Maury Raycroft
Biotech Analyst, Jefferies

Or some of the levers that could potentially get you lower on expenses too.

Howard Horn
CFO, Ultragenyx

Yeah. The, yeah, obviously, if you choose not to do a program or you choose not to go into a region or expand something, or if you chose to reduce on spend. It is all the normal levers.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Okay. Okay, and for CRYSVITA, third quarter revenues came in at $109 million. How much of the shortfall was North American shipment timing and other technical issues versus true underlying demand? What are you seeing in fourth quarter so far that gives you confidence in the strong rebound of about $142 -$162 million?

Howard Horn
CFO, Ultragenyx

Yeah, I think importantly, we give full-year guidance, and we, at the outset of the year, said for CRYSVITA, $500 -$520 million, and we have reiterated that each quarter, and we did so again in our third quarter call. We feel good about the full-year part of it. Maybe what you are asking is, we talked about a sawtooth pattern that goes through the four quarters of the year, and that is driven by ordering patterns in some regions and seasonality in others, and we followed that pattern. The concept of a shortfall is not the way I would think of it. It has followed the sawtooth we predicted.

Emil Kakkis
CEO, Ultragenyx

Two and four is higher, one and three is a little bit lower. It has been that way forever, but there is always a little bit of lumpiness in Latin American ordering, and maybe even some that went into Q2, less Q3. There is another factor that our actual royalty rate does rise through the year, so fourth quarter always is bigger for us because the royalty at the beginning of the year, it starts at a lower point, actually goes up as time goes on through the year, because of the way the royalty is designed. We are comfortable that we are going to hit the mark.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. You mentioned the 20% growth rate. I guess, how much growth is from new patient starts versus geographic expansion and persistence?

Emil Kakkis
CEO, Ultragenyx

It depends on the product. I think MEPSEVII has been pretty stable, so that is not an issue. For Dojolvi, a lot of the growth in the U.S. is maybe single digit, but we are adding Japan is in launch mode right now. So additional territories for Dojolvi, Middle East and Japan have been growing that product particularly. CRYSVITA has been growing in Turkey and Latin America through just new patient starts continuing. EVKEEZA has been growing in both Japan and in Europe. In fact, last year, EVKEEZA kind of outperformed, and that kind of helped us. So, it is addition of territories and it is organic growth, the combination that is adding.

What has been encouraging is things like the amount of Middle East work has really, we are talking about the Middle East a lot for other reasons, but we have Dojolvi patients in Kuwait and Dubai and Kingdom of Saudi Arabia as well, as well as Turkey. We have some of our programs in Middle East doing better than we would normally think about, right? That has been definitely a plus. Canada has done well too, which normally we do not, in rare disease, we do not think of Canada, but with the private insurance situation, we are actually getting more traction in Canada and doing well there as well.

These outlying areas are still building up revenue and adding to the story, which is why, from our beginning, we wanted to be a global story, because once you de-risk, then you can generate revenue streams for all these different countries, because everyone has kids that need to get treated and want to get treated, right? There's that level of urgency that always drives it. We think now we're in that point of leveraging that commercial infrastructure and building up a real global business. Then every year, different territories, additional products or territories, or just organic growth will help drive our business forward. That's why, if you look at our deck, you can see the steady growth of our revenue, which is just continuous organic addition of patients at additional territories and countries that we're in, as well as new products coming out.

I think it's been a really solid part of our story and maybe not fully valued.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Makes sense. With Crysvita, maybe talk about just where peak sales could go there. So, prior to 2032 loss of protection on the IP, and with Kyowa Kirin, they've got a next-gen antibody, but what else is there out there in the XLH space, and how do you think about competition?

Emil Kakkis
CEO, Ultragenyx

Well, Crysvita is an excellent product, and really it's like a second-generation antibody. It's fully bioavailable subcutaneously, has no anti-drug antibodies, no hypersensitivity. It's a really beautiful drug, and with high compliance and persistence, because once you get your phosphate to normal, you feel good, and if you lose that, you feel it, right? There's an immediate short-term impact to people, which is why that drug's done so well. It's continuing to grow everywhere, and I think the U.S. is going to continue to grow. We just got the Q2W dosing in the U.S., and there's a lot of patients going onto that, which will increase revenue. We have new bowing data from the PEDS, which I think should drive more pediatric adoption, because we think there's room even just in the U.S. to get more penetration. We've talked to our colleagues at Kyowa Kirin about that, and they're agreeing.

Crysvita continued to grow. It has not stopped at all, and it is continuing to grow. We feel good about that continuing. With regard to LOE, in rare disease drugs, it is never quite the same as other really large market drugs. These are all specialty pharmacy patient drop ship, and specialty pharmacy related. They are not going through the traditional wholesaler channels and prescription process, right? It is a very different thing. They generally do not have the same LOE effect that you might see for others. That said, we are not ignoring it. Kyowa Kirin has been working on molecules, and we have been working on molecules.

We have new versions, but we have to meet the standard of the product we have, which I have just told you is excellent, and now you want to make it better, maybe less frequent dosing, but maybe a little more potent to try to enhance the efficacy. We are working on it together, and we would expect to be able to get something launched in time before LOE occurs, and that we could put out and move forward. We are preparing for it. We understand it is there. I do not think it is as big a risk as some think, but we are still covering it. We will take care of it.

Maury Raycroft
Biotech Analyst, Jefferies

Would the economics be the same, or would that-

Emil Kakkis
CEO, Ultragenyx

There are probably some subtle differences because we are in a different stage of the company, in different place, and who is doing what is different. But we will come up with, I think, reasonable economics that will reflect the value of both parties and the economics that are good for both. I am sure we can do that. We have had a good partnership, and we have done very well together all these years. Part of it is just because they developed a great product, but we were good at getting it developed efficiently and fast. That partnership, we have a share of how we get this done, and I think that can continue, and we can still share the rights and the value for global work that we are doing together.

Maury Raycroft
Biotech Analyst, Jefferies

More updates on that next year, or?

Emil Kakkis
CEO, Ultragenyx

Yes, we could presume so, yes, sometime next year. I mean, they're still doing the work in the phase II next year. Somewhere between there and the year after, we'll be going hardcore into what needs to be to get to approval. The idea to get approval, the LOEs, the first one is 2032, and there's one that comes after that for a second patent, but...

Maury Raycroft
Biotech Analyst, Jefferies

2035.

Emil Kakkis
CEO, Ultragenyx

The second one.

Yeah. Our goal would be to get launched before those timeframes, which we think we can do. We did the original development, keep in mind in four years. We think we can get this part done in that timeframe too.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. Let's shift gears. We'll talk about some of your programs. There's been renewed interest in setrusumab. For that one, where exactly are you in the FDA process today, and have you had a formal Type B meeting yet, or when could that happen?

Emil Kakkis
CEO, Ultragenyx

Well, one thing, we've had multiple meetings with FDA. The Type B meeting is a milestone-based meeting, right? That's like pre-BLA meeting or an end of phase II meeting, right? Those are milestone meetings. When it's not a milestone meeting, they're usually called Type C meetings or Type D meetings if they have a narrow focus, but who cares about the regulatory name? We met with them a couple times. We're working through that process. We're talking about what's required. We have said in the past FDA had wanted some additional prospective data. The question is, what does that truly constitute? We haven't settled because we're trying to figure out how to get there quickly. We expect there to be more trial data in our plan next year, and budget-wise, it covers the potential of a study.

It's already built in, right, into our budget plan and our profitability plan, just to be clear. We are still collecting data on patients. 80% of the patients stayed on drug, want to stay on, do not want to come off, and the PIs are very dedicated to it. There's a lot of strength behind the desire for that product. We are going to find a way to get through. What we're trying to do is find how to get it as promptly through, but I don't think I'd want the street anticipating that it's going to get filed soon. What I want them to understand, there is probably some data we have to collect, but how much it is, how long it takes, that'll be some of the things we'll have to figure out.

But we are dedicated to getting it done because we think setrusumab is a meaningful product for OI, and I think the PIs are supportive of that as well as the patients.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. And if we look at the data, the three or greater prior fracture subgroup stands out. Can you talk more about this population beyond fracture history, and does this population, is there anything beyond the fractures that biologically or clinically makes them distinct?

Emil Kakkis
CEO, Ultragenyx

Well, first, let's talk about the ORBIT study. The ORBIT study was designed to have a minimum level of fractures, which was meant to be at least one, and our thought of the average would be about two if you have a threshold of one that the average. What ended up happening, the average was like 0.5. That's part of the way the study failed. We did not have as much fracture as we could. Now, we built in the study a strata of greater than three or below three, right? We stratified by greater and below three. Three is a number we already have been talking about. When you look at the above three strata, you saw a meaningful treatment effect, right? It's in the 40%-60% range. We see a meaningful treatment effect there.

Had the whole study had that strata, the study would have been successful, but unfortunately, we had too many mild patients. We think that that severity is a very common issue in rare disease programs where you do not quite get enough severity and have enough signal. But we feel that the more significantly fracturing patients have a meaningful decrease, it's in the 40%-60% range. And the same was true for the COSMIC study. That study showed an even bigger effect, again, in the higher fracture subset. All we are saying is the patients that really have enough fractures where you can measure the events, we see the treatment effect in the 40%-60% range, which is what we were thinking we would have all along. It tells us why it did not work, but it tells us that it does work. The BMD effects are profound.

One Z-score improvement, P-value is very strong. What was supportive beyond fractures was that the pain of physical function scores, there were two endpoints in ORBIT, and this is a placebo-controlled trial. Both endpoints were either statistically significant or at least trend, and that showed us that there's a pain physical function effect in the ORBIT study. However, we missed the primary AFR endpoint that was chosen, and this was chosen historically by the way FDA looks at osteoporosis, really, because it's a very narrow kind of view. We've been discussing how to look at fractures, what about clinical benefit in general at OI, and how to interpret our data to get them to appreciate and understand the data, and that's where this has gone.

What we can show is that the things like the vertebral column, where the bone mineral density increases very quickly, we see a very profound effect on vertebral column, which is extremely important, especially in little kids. The long bones may take more time, and so depending on the bone and the timeframe, this is factors in OI. What I can say is that whether you think about pain, physical functioning, fractures in different bones, we see an effect that's pervasive across the patients, and we think then there's a drug we just need to investigate with FDA, how do we get the support for this? How fast can we get it to make it accessible to patients? We're confident we can get there. Just how fast is a question that I think everyone's wondering about.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. I guess with the data that you're collecting from the current study, including the open-label extension, do you think that should be sufficient, or do you think you're going to need another study? I guess, what's the base case scenario going forward?

Emil Kakkis
CEO, Ultragenyx

Well, I think the base case, people just assume that there's more clinical trial data to collect. That's, I think, the base case. The crossover data is another piece of data that's coming that will be additional group of patients who are a control arm that went over onto drug. It's an additional piece. Will that be enough? It's not a parallel control type design, right? It's crossover data. I think that could be helpful. However, FDA's tendency is to want prospective controlled data, not crossover type data. In rare, in multiple programs I've been involved with, we have used crossover data to help support efficacy case statements. FDA is always a show-me situation. You don't get answers by asking hypothetical questions. You got to show them the data and negotiate.

Just to be clear, you don't, with FDA negotiating, the idea that you go to one meeting, everything's solved, is very simplistic. When things are complex, it can take a little bit of time. Our goal is to work with the FDA closely to find a good and more rapid path. I would not assume that right now, but I think the crossover data is another piece of data that we can bring to the table. There were around, of the peds, there were about 30-some patients in the ORBIT study that were pediatric, and there were then another 36 that were in the COSMIC study on the bisphosphonate arm. Those patients have crossed over and are being treated now.

That gives us another bite at the apple, if you will, another group of patients that were treated we can show and compare what they had. The patients are very happy to have crossed over, by the way, and I went to the OIF meeting and talked to a lot of families who actually earned the crossover and how important it was to them. The community gave us an award for the work we're doing with them. I think the truth is, OI has just not had much, and this is something that's doing something more profound than you've ever had. We have a responsibility to get there, both for the patients and for, of course, investors that watch us.

Maury Raycroft
Biotech Analyst, Jefferies

If FDA wants another prospective study, could you use the current dataset for accelerated approval and then potentially do a post-marketing commitment for that study? Is that possible, or?

Emil Kakkis
CEO, Ultragenyx

It's one possibility. I don't want you to create that as the base case, because I think that's a lower probability case, but obviously better case, b ut I don't want that to be the expectation at this point. I think we should expect they may need more prospective data. I do think we should be able to try to leverage it, but I don't think you should expect that at this point.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. When is the next OLE data cut? As far as the crossover data from there, has FDA commented on that and how meaningful that would be?

Emil Kakkis
CEO, Ultragenyx

We haven't provided any crossover data yet.

Maury Raycroft
Biotech Analyst, Jefferies

Just the idea.

Emil Kakkis
CEO, Ultragenyx

It would need to be at least a year. Crossover data they know doesn't have a parallel control arm, right? Their natural reaction to that is that it's not as valuable. The FDA always says certain things, and there's a dance and a chess game that goes on in terms of understanding. That's what they say. Let's see what it looks like. We have gotten data from crossover design. The original Crysvita approval for pediatrics were patients on oral phosphate, and they crossed over onto drug. That was the approval trial. All right? But originally, they said no, but then eventually we got them to say yes, because the data were compelling. I think a discussion with the FDA with data that's compelling is always a better place to be than trying to get hypothetical agreements.

This is why you have to understand; I've negotiated a lot of FDA agreements. Eric and I both, Eric's our CMO here. You have to understand how they have to operate. They need certainty. They can't make agreements to things that they don't know, they can't see in their hand. When we get the crossover, we'll be able to look at them, talk through it. Whether that gets us to a file, I think is a question I would say. I would not assume that. I would assume that another trial is probably needed. Right now, we're working it, and when we get an answer, we'll let you know.

Maury Raycroft
Biotech Analyst, Jefferies

Okay. That sounds good. Let's shift gears. We'll talk about the gene therapy launches underway. Maybe, provide some perspective on how those are going, and wondering how many patients have been identified, referred to a QTC, and are scheduled to treatment to date f or treatment.

Emil Kakkis
CEO, Ultragenyx

First of all, our choice of gene therapies are things that I think are patient urgent. The thing that drives gene therapy success so far has been urgency. Is this the only way to get them treated? FAYUVI for Sanfilippo, they're dying. Those kids are going to die of their brains, a lot like SMA. GSD1 is also urgent, maybe not as urgent as FAYUVI. We're having lots of start forms, and FAYUVI particularly, because it's so crazy urgent, we have already treated multiple patients. So far, I think the launch is going well. We'll provide The QTCs are more than 30, and we expect to have 40 by the end of the year. Early next year, we'll provide where we are on QTCs, where we are on start forms, and revenue that we'll have from this year. We'll announce then. We won't project the launch trajectory of products.

We don't do that for the first six quarters. It's our habit. So far, I think they've gone well, and we're pleased with what we're seeing. Did I miss anything?

Howard Horn
CFO, Ultragenyx

Nope, you got it.

Emil Kakkis
CEO, Ultragenyx

Okay.

Maury Raycroft
Biotech Analyst, Jefferies

Where are the biggest drop-offs or delays in the funnel to get patients on therapy? These are high-priced drugs. Has reimbursement or payer requirements been a bottleneck?

Emil Kakkis
CEO, Ultragenyx

Well, no. We did a lot of conversations. I personally was involved in the payer conversations during the summer, and I go to try to raise the caliber of who's on the other side, so we get decisionmakers on the other side. Usually, if we see outcomes, they will do that. We had a lot of discussion with the major plans to make them understand the urgency and the situation, and I think we got their understanding. When you go to launch, though, you're always being approved under exceptions, right? those processes take some time, right? That's a time thing, but right now, we haven't seen reimbursement as a block. We've had good reimbursement success, and I think the policies seem to be coming to label so far. We're encouraged by how it's looking. We don't think that is going to be a problem.

I think it's sites getting set up and ready to treat. You have to get antibody testing done and some certain other things. But so far, I think it's gone pretty well, and patient urgency is driving the story.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. You've invested heavily in internal manufacturing. At what annual patient volume can the gene therapy products reach biologics like COGS and gross margins?

Emil Kakkis
CEO, Ultragenyx

Well, we invested appropriately, because the truth is, gene therapy products are expensive to make, and it's far better to keep those kind of complex products under your own control. We contract manufacture most of the other products, right? In this case, very high-cost, complex products, you're better off in your control from a margin standpoint and just a cost control and flexibility standpoint. It's just always been the case. We did it where we needed to do it, but we are very thoughtful on business decisions on manufacturing. We don't just do it just to have it control. It has to make business sense. The plant we built, we think we can leverage. It's appropriately sized to leverage, and we're able to make the drug substance and drug product for the GENGLYCOS product.

The drug for FAYUVI, it's made. The drug substance is actually made at our partner, and we do the drug fill finish. The capacity there is sufficient capacity to what we need. If demand continues and grows, it's possible we will need to increase the amount of our partner drug substance production to keep up. So far, I think we've been pretty well sized, and I think we'll be in good control. Did I miss anything on the financial aspects of that? I think one of the things that's very important to understand our burn, because people talk about our cash burn in the last couple years, but the last couple years, we've been developing launch material for four products, right?

Two of those are approved, so we've expensed a lot of product that we've put on our product balance sheet, if you will, not on the cash balance sheet. That product is now what's going to be sold now through next year. It's all expensed product. A lot of the spend that happened in the last couple years are actually product that we will be able to use, and I think that's important that people understand that there's some hidden value that's coming back to us now.

Maury Raycroft
Biotech Analyst, Jefferies

Makes sense. On the BD front and just kind of replenishing the pipeline, any more perspective on that that you want to share?

Emil Kakkis
CEO, Ultragenyx

We have been a really good engine for innovation. We have a couple programs that are already taken through IND enabling, that we mentioned. We are going to be very smart about operating the footprint. As long as everything goes well, we have the potential to have two more INDs already ready to go. One is for creatine transporter deficiency, the other for CDKL5 deficiency. Both are 30,000 to 50,000 kind of population size, and we think of as potential billion-dollar rare disease programs, and totally unmet needs, untreated drugs, and we have created those drugs. We will always be opportunistic in BD, but we are going to be smart about choices. We are not going to build out a whole bunch of new product. We are going to stick to our profitability goals. If we do need deals, they have to be very smart value-creating deals.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Maybe just closing out, we are out of time, if you want to comment on cash position and key catalyst side.

Howard Horn
CFO, Ultragenyx

Yeah. We concluded the quarter with $401 million. We were able to add to that another $350 million net from our two PRV sales. As Emil mentioned, it is a good strong balance sheet, and we plan to add to it.

Maury Raycroft
Biotech Analyst, Jefferies

Got it.

Emil Kakkis
CEO, Ultragenyx

Around $700 million, we got plenty of cash, and we will be adding cash next year. I think we are in a great place from all around running the business, and I am happy to be a company that is going to be driven by six products, profitable, global rare disease company, and done that in 12 years. I think that is a real win. We do have to deliver some catalyst upsides. I appreciate that, and we are going to work toward getting that as well.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Emil, Howard, thanks so much for joining us today.

Howard Horn
CFO, Ultragenyx

Thanks, Maury.

Emil Kakkis
CEO, Ultragenyx

Thank you.